Amisulpride Augmentation in Schizophrenia Patients with Poor Response to Olanzapine: A 4-week, Randomized, Rater-Blind, Controlled, Pilot Study

Amisulpride Augmentation in Schizophrenia Patients with Poor Response to Olanzapine: A 4-week, Randomized, Rater-Blind, Controlled, Pilot Study

Introduction Olanzapine (OLA) is a common first-prescribed antipsychotic and has shown favorable efficacy in acutely exacerbated patients with schizophrenia. The mixed receptor activity of OLA and its greater affinity for serotonin 5-HT2A rather than dopamine D2 receptors are similar to those of cl...

Full description

Bibliographic Details
Main Authors: W.-M. Bahk, Y. S. Woo, S.-Y. Park, B.-H. Yoon, S.-M. Wang, M.-D. Kim
Format: Article
Language:English
Published: Cambridge University Press 2023-03-01
Series:European Psychiatry
Online Access:https://www.cambridge.org/core/product/identifier/S0924933823023222/type/journal_article

Internet

https://www.cambridge.org/core/product/identifier/S0924933823023222/type/journal_article

Similar Items